Researchers at Dana-Farber Cancer Institute collaborated with multiple institutions to pinpoint rare germline structural ...

Singapore-based biotechnology company CytoMed Therapeutics has signed a five-year business and research collaboration ...

Mirror Biologics, Inc., specializing in development and manufacturing of immunotherapy products where the active ingredient ...

Instead, we're recruiting healthy soldiers from disease-free, well donors and equipping them with special targeting systems ...

Instil Bio’s stock surged over 25% on Tuesday to levels last seen in early December after Jefferies upgraded the shares to ...

BGBC-354 is under clinical development by BeiGene and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 69% phase transition success rate (PTSR) ...

FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.

The FDA approved subcutaneous nivolumab for solid tumors, tiselizumab for advanced gastric and GEJ cancers, and key 2024 breast cancer breakthroughs are reviewed. Experts provide perspective on ...

Trastuzumab pamirtecan is under clinical development by BioNTech and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 37% phase transition success ...

On December 20, 2024, the FDA granted accelerated approval to the combination of encorafenib (Braftovi), cetuximab (Erbitux), ...

Opdivo Qvantig is approved for solid tumors, including melanoma, renal cell carcinoma, and non-small cell lung cancer. The ...

The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for ...